Research programme: CRAC channel antagonists - CalciMedica

Drug Profile

Research programme: CRAC channel antagonists - CalciMedica

Alternative Names: CRAC channel inhibitors - CalciMedica

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CalciMedica
  • Class Small molecules
  • Mechanism of Action Immunosuppressants; ORAI1 protein inhibitors; STIM1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; CNS disorders; Inflammation

Most Recent Events

  • 01 Mar 2011 A lead compound from this programme has entered clinical development
  • 30 Sep 2009 TorreyPines Therapeutics Inc has merged with Raptor Pharmaceuticals Corp to form Raptor Pharmaceutical Corp
  • 13 Oct 2008 CalciMedica exercises option to acquire additional intellectual property from TorreyPines Therapeutics for use in CNS disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top